INTRODUCTION
By using genome-wide analysis, two groups of investigators identified a subtype of B-cell acute lymphoblastic leukemia (B-ALL) termed "BCR-ABL1-like" or "Ph-like" ALL, which has a gene expression profile similar to that of Philadelphia chromosome (Ph) -positive ALL but lacks BCR-ABL1 fusion protein expressed from t(9; 22)(q34.1;q11.2) and accounts for 10% to 15% of childhood B-progenitor ALL.
1,2 Similar to Phpositive ALL, BCR-ABL1-like ALL is characterized by a high frequency of alterations of the IKZF1 gene, which encodes the early lymphoid transcription factor IKAROS, and a high risk of relapse when treated with conventional chemotherapy.
(IGH-CRLF2) or as a focal deletion resulting in the expression of a P2RY8-CRLF2 fusion transcript. 4, 5 Among patients with CRLF2 rearrangement, approximately half have concomitant activating mutations of the Janus kinase genes, JAK1 or JAK2, resulting in activation of JAK-STAT signaling. [4] [5] [6] Recent transcriptome and whole-genome sequencing genomics of BCR-ABL1-like patients without CRLF2 rearrangements identified a diverse array of genetic alterations that activate cytokine receptor and tyrosine signaling. 3, 7 Because of the lack of uniform definition and different gene expression classifiers used by various groups of investigators, each study of BCR-ABL1-like ALL comprised a different, albeit overlapping, cohort of patients.
Although the prognostic impact of high CRLF2 expression varied according to the study cohort, 8, 9 BCR-ABL1-like ALL has been consistently associated with poor treatment outcome in all studies reported to date 1, 2, [9] [10] [11] [12] [13] In this study, we examine the clinical heterogeneity and prognostic impact of BCR-ABL1-like ALL treated in the context of an effective risk-directed protocol based on minimal residual disease (MRD) levels measured during remission induction therapy.
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PATIENTS AND METHODS
Patients
From June 2000 to October 2007, 498 evaluable patients (1 to 18 years of age) with newly diagnosed ALL were consecutively enrolled onto the Total Therapy XV study at St. Jude Children's Research Hospital or at Cook Children's Medical Center.
14 This study was limited to patients with B-ALL because all BCR-ABL1-like patients have B-lineage immunophenotype. Of the 422 patients enrolled onto the Total Therapy XV study with B-ALL, 344 (81.5%) had adequate samples to screen for the expression profile of BCR-ABL1-like ALL (Fig 1) . The protocol was approved by the institutional review boards. Signed informed consent was obtained from the patients who were 18 years old or from the parents or guardians of younger patients, with assent from the patients, as appropriate.
Diagnosis and Risk Classification
The diagnosis of ALL was based on morphologic, immunophenotypic, and genetic features of leukemic blast cells, as described previously. 15 determined by the level of MRD during and after remission induction therapy. Any patient with Ն 1% leukemic cells in the bone marrow on day 19 of remission induction or 0.01% to 0.99% residual leukemia after completion of 6-week induction therapy was considered to have standard-risk ALL. Patients with Ն 1% residual disease after completion of induction therapy were assigned to the high-risk group.
Treatment
Details of the treatment regimen have been described previously. 14 In brief, patients with Ն 1% residual leukemia in the bone marrow on day 19 of remission induction were given three additional doses of asparaginase. At the end of induction (between days 43 and 46), bone marrow aspiration was performed to assess MRD level, and consolidation therapy with high-dose methotrexate and daily mercaptopurine was given for four courses. Low-risk and standard-risk patients then received risk-directed continuation therapy, and high-risk patients were offered the option of allogeneic hematopoietic stem-cell transplantation. All patients received early triple intrathecal therapy, and none received prophylactic cranial irradiation.
Identification and Genomic Characterization of BCR-ABL1-Like ALL
Single nucleotide polymorphism 500K or single nucleotide polymorphism 6.0 microarrays and U133A gene expression profiling (Affymetrix) were performed in all patients with suitable genomic material available to identify copy number alterations and distinct genetic subgroups by using reference normalization 18 and circular binary segmentation, 19 as previously described. 1, 20 Prediction analysis for microarrays was used to identify patients with BCR-ABL1-like ALL with a gene expression profile similar to that of BCR-ABL1 ALL. 3, 21 Sequence mutation analysis for genes known to be mutated in B-ALL (including IKZF1, PAX5, and JAK2) was performed for all patients with available material, including 16 patients with BCR-ABL1-like ALL, 12 of whom were also studied with next-generation sequencing. Genomic polymerase chain reaction (PCR), Sanger sequencing, and mutation detection were performed as previously described. 6,20,22 CRLF2 rearrangements were identified by genomic PCR, real-time PCR, and fluorescent in situ hybridization, as previously described.
5 Next-generation sequencing was performed by the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project, as previously described, 23-25 with messenger RNA (mRNA) sequencing in seven patients, whole-genome sequencing in five patients, and both mRNA sequencing and whole-genome sequencing in nine patients (Appendix Table A1 , online only). Fusion transcripts were identified from mRNA sequencing data by using CICERO, a novel analysis algorithm (Li et al, manuscript in preparation). Putative fusions were confirmed by real-timePCRandbidirectionalSangersequencing.Sequencedataaredepositedat the European Genome Phenome archive, accession EGAS00001000654.
Statistical Analysis
Event-free survival and survival from diagnosis were estimated by the method of Kaplan-Meier, with associated SEs calculated by the method of Peto and Pike. The cumulative incidence functions of relapse were estimated by the method of Kalbfleisch and Prentice, 26 and the functions were compared by using Gray's test. Deaths in remission were considered competing events in the estimation of cumulative incidence of relapse. Outcome data updated on August 23, 2013, were used for this analysis. The median follow-up time for patients remaining in continuous remission was 8.2 years (range, 1.3 to 12.9 years). At the time of analysis, 95% of the survivors had had a follow-up visit within 2 years; only 2.0% of the patients lacked a documented contact within the previous 5 years. 
RESULTS
Presenting features and treatment outcome of the 344 patients who were evaluated for the gene expression profile of BCR-ABL1-like ALL were not significantly different from those of the 78 patients who were not (data not shown). Of the 344 patients with B-ALL who were evaluated, 40 (11.6%) had BCR-ABL1-like ALL. Table 1 summarizes the clinical and biologic features as well as treatment and outcome of these 40 patients (27 males and 13 females). Their median age was 5.3 years (range, 1.3 to 18.6 years), and median presenting leukocyte count was 7.1 ϫ 10 9 /L (range, 1.7 to 258.3 ϫ 10 9 /L). Compared with other patients with B-ALL, those with BCR-ABL1-like ALL were more likely to be male (P ϭ .04), have Down syndrome (P ϭ .003), and have higher MRD on day 19 (P ϭ .009) and at the end of induction (P ϭ .001; Table 2 ). There was no significant difference in the distribution of the risk groups between patients with BCR-ABL1-like ALL and those with other B-ALL on the basis of initial risk classification of the protocol (P ϭ .41) or NCI risk classification (P ϭ .61). However, after including response to remission induction based on MRD levels in the risk-classification algorithm, patients with BCR-ABL1-like ALL were more likely to be classified as having standard-or high-risk ALL (P ϭ .02; Table 2 ).
All six patients with high-risk BCR-ABL1-like ALL received hematopoietic stem-cell transplantation. The proportion of patients with BCR-ABL1-like ALL who received a transplantation (15%) was significantly higher than 4.3% for the other patients with B-ALL treated in the same protocol (P ϭ .015). Adverse events among patients with BCR-ABL1-like ALL included hematologic with or without CNS relapse in four patients (No. 4, 5, 23, and 27), two deaths in remission (No. 34 and 36), and one induction failure (No. 39).
None of the 40 patients had t(1;19)(TCF3-PBX1), t(4; 11)(MLL-AFF1), or t(12;21)(ETV6-RUNX1); 11 had hyperdiploidy with gain of at least five chromosomes. Of the 40 patients with BCR-ABL1-like ALL identified by gene expression profiling, 11 (27.5%) harbored a genomic rearrangement of CRLF2, including nine patients with P2RY8-CRLF2 and one with IGH-CRLF2. An additional patient had marked CRLF2 overexpression suggestive of rearrangement but was negative for these alterations. Six of these patients with deregulated CRLF2 had concomitant JAK mutations, including JAK2 p.Arg683Gly (four patients), 683Ser (one patient), and JAK1 p.Val658Phe (one patient).
Twenty-five patients with BCR-ABL1-like ALL had suitable material for detailed genomic interrogation and sequencing, including 14 patients who lacked CRLF2 rearrangement. Four patients had fusion transcripts responsive to ABL tyrosine kinase inhibitors, including SSBP2-PDGFRB (patient 12), SSBP2-CSF1R (patient 33), EBF1-PDGFRB (patient 38), and NUP214-ABL1 (patient 40). Two patients had genetic lesions predicted to be responsive to JAK inhibition: IL7R p.Val253Gly and JAK1 p.Ala428Pro (patient 7) and IL7R p.Ile241_Ile245delinsCysLeuCys (patient 25). Seven patients harbored mutations activating Ras signaling (patients 6, 11, 13, 18, 23, 28, and 30). Three patients lacked a kinase activating lesion on mRNA sequencing or whole-genome sequencing (patients 16, 29, and 39). Of the four patients with BCR-ABL1-like ALL with high hyperdiploidy, two had alterations in the Ras pathway with a complex FLT3 mutation (patient 6) and NRAS p.Gln61Lys substitution (patient 11). Collectively, of the 25 patients subjected to detailed genomic profiling and sequencing, 22 (88%) had cytokine receptor, kinase, or Ras alterations.
Seven (27%) of 26 patients with BCR-ABL1-like ALL studied had deletion of IKZF1, a frequency markedly lower than that of patients with BCR-ABL1-like ALL in previous pediatric cohorts. 1, 7 Seven patients had other lesions involving the B-lineage transcription factor genes PAX5 and EBF1 and, collectively, 11 (42%) had one or more lesions in this pathway.
Despite inferior response to remission induction therapy as shown by overall higher levels of MRD (Table 2) , patients with BCR-ABL1-like ALL did not have a significantly inferior event-free survival or overall survival compared with patients with other B-ALL subtypes (Figs 2A and 2B ). Even when treatment outcome was analyzed separately within the three risk groups, no significant differences in eventfree survival or overall survival between the two groups were noted (Table 3) .
Consistent with the above results, the cumulative risk of isolated hematologic relapse or any relapse did not differ significantly between patients with BCR-ABL1-like ALL and those with other B-ALL subtypes, regardless of whether these parameters were analyzed including all patients (Figs 3A and 3B) or separately within the three risk groups (Table 4) . Similar results for the comparison of event-free survival, overall survival, and cumulative risk of relapse were obtained after exclusion of the 10 patients with Down syndrome or those with specific translocations including t(1;19)(TCF3-PBX1), t(4;11)(MLL-AFF1), t(12;21)(ETV6-RUNX1), and t(9;22)(BCR-ABL1) (data not shown).
In multivariable analyses, including known prognostic factors in the Total Therapy XV study (the presence of BCR-ABL1, MRD Ͼ 5% on day 19 of induction, MRD Ͼ 0.01% on day 46 of induction, IKZF1 alteration, and BCR-ABL1-like ALL), only MRD more than 0.01% on day 46 of induction was independently associated with poor survival (hazard ratio, 5.18; 95% CI, 1.59 to 16.9; P ϭ .006; Appendix Table A2 , online only).
Among patients with BCR-ABL1-like ALL, the only prognostic factor is the presence of MRD more than 5% on day 19 of remission induction. The nine patients with MRD more than 5% on day 19 of induction had inferior event-free survival (66.7% Ϯ 14.5% v 96.7% Ϯ 3.3% at 5 years; P ϭ .006) and inferior overall survival (77.8% Ϯ 13.0% v 96.7% Ϯ 3.3%; P ϭ .008) compared with the other 30 patients with lower MRD levels. Event-free survival was not significantly different between the 11 patients with and the 29 patients without rearrangement of CRLF2 (90.9% Ϯ 8.3% v 89.7% Ϯ 5.9% at 5 years and 90.0% Ϯ 15.8% v 76.8% Ϯ 14.0% at 10 years; P ϭ .40). The seven patients with IKZF1 alterations tended to have a poorer event-free survival than the 19 patients without IKZF1 alterations (71.4% Ϯ 15.6% v 100% Ϯ 0.0% at 5 years and 71.4% Ϯ 27.0% v 94.7% Ϯ 8.9% at 10 years; P ϭ .08).
DISCUSSION
This study demonstrates that the adverse prognosis of pediatric BCR-ABL1-like ALL can be improved by effective risk-directed therapy based primarily on MRD levels during and at the end of remission induction therapy. It should be noted that our patient population and their risk assignment may be different from those of previously reported studies. In contrast to prior studies that selectively examined BCR-ABL1-Like Acute Lymphoblastic Leukemia www.jco.org high-risk B-ALL and did not apply MRD measurement for riskdirected therapy, 1,2,10,27 this study included all patients with newly diagnosed ALL and used MRD level to direct intensity of therapy. In this regard, patients with BCR-ABL1-like ALL in this study do not have a significantly higher frequency of NCI high-risk ALL at diagnosis compared with patients with other B-ALL subtypes. However, a high proportion of patients with BCR-ABL1-like ALL in this study were subsequently classified as having higher-risk leukemia (standard or high risk according to Total Therapy XV criteria) based on MRD levels during and after completion of remission induction therapy.
Patients with BCR-ABL1-like ALL in Total Therapy XV had the same proportion of high hyperdiploidy as did other patients with B-ALL but lacked other genetic abnormalities with prognostic or therapeutic implications such as t(1;19)(TCF3-PBX1), t(4;11)(MLL-AFF1), and t(12;21)(ETV6-RUNX1). A notable finding was a lower frequency of CRLF2 (27.5%) and IKZF1 (27%) alterations in BCR-ABL1-like ALL than in prior studies (approximately 50% and 70%, respectively). This may, in part, reflect differences in study cohorts, because prior studies selectively examined high-risk ALL, included patients older than 18 years, and were enriched for patients of Hispanic ethnicity (22% to 29%) treated in clinical trials by the Children's Oncology Group. 1, 3, 10 In this regard, in the Children's Oncology Group studies, Hispanic patients with high Native American genetic ancestry have a high frequency of rearrangements of CRLF2 28 and inherited GATA3 rs3824662 risk allele, 29 which were associated with BCR-ABL1-like ALL and inferior treatment outcome. In contrast, the Total Therapy XV study enrolled consecutive patients 1 to 18 years old from all risk groups and had a relatively low frequency (14.5%) of patients with Hispanic ethnicity.
In a risk classification schema based solely on the presenting age, initial leukocyte count, and conventional cytogenetic and molecular genetic features, approximately 60% of our patients would have been treated as having low-risk ALL. Thus, many of the patients with BCR-ABL1-like ALL in the other series with resistant leukemia might not have received intensive treatment because they were not recognized as a result of a lack of response evaluation. By contrast, the Total Therapy XV study used MRD measurements for risk-directed treatment. With this additional information, only 40% of the patients received treatment for low-risk ALL, and the remaining patients were treated with Abbreviations: ALL, acute lymphoblastic leukemia; MRD, minimal residual disease; NCI, National Cancer Institute. ‫ء‬ Genetically determined race/ethnicity using the single nucleotide polymorphism-based ancestry information.
†Based on MRD levels measured on days 19 and 46 of remission induction.
BCR-ABL1-Like Acute Lymphoblastic Leukemia
www.jco.org more intensive therapy for standard-risk (45%) or high-risk (15%) ALL. With improved risk assessment based on MRD measurements, comparable results between BCR-ABL1-like ALL and other B-ALL subtypes were achieved in the Total Therapy XV study; these results extended to all three risk groups (Tables 3 and 4) . Therefore, for centers that lack the capability to identify BCR-ABL1-like ALL, excellent overall treatment results can still be achieved, provided that reliable methods for monitoring MRD are available. However, we argue that it is still clinically important to identify BCR-ABL1-like ALL because many of these patients harbor genetic lesions that are sensitive to tyrosine kinase inhibitors (eg, ABL1 and PDGFRB rearrangements) or JAK inhibitors (eg, EPOR, IL7R, JAK2, and SH2B3 that activate JAK-STAT signaling) in preclinical models using cell lines and human leukemic cells. 3, 7, 30, 31 The incorporation of these agents in the treatment of patients with targetable lesions could potentially help reduce the intensity of chemotherapy. Although our series had only a limited number of refractory or relapsed patients and was not large enough to capture the full spectrum of targetable lesions, anecdotal reports of refractory BCR-ABL1-like ALL that responded well to tyrosine kinase inhibitors are already emerging.
32-34 Because of their high level of MRD at the end of remission induction, six (15%) of the 40 patients with BCR-ABL1-like ALL in this series received hematopoietic stemcell transplantation, a proportion much higher than 4.3% for the other patients with B-ALL treated in the same protocol.
14 Conceivably, identification of patients with BCR-ABL1-like ALL with targetable genetic lesions followed by treatment with tyrosine kinase inhibitors or JAK inhibitors might avoid transplantation in some of these patients, similar to the use of tyrosine kinase inhibitors in BCR-ABL1-positive childhood ALL, which have improved outcome and reduced the number of patients requiring transplantation. 35, 36 Of note, among four of the six patients with BCR-ABL1-like ALL who received transplantations and were retrospectively tested for genomic lesions in this series, two had fusion transcripts that would respond to ABL tyrosine kinase inhibitors.
Only two of 16 low-risk patients with BCR-ABL1-like ALL treated with an antimetabolite-based regimen in this series (and one of six females 1 to 3 years old with the ZMIZ1-ABL1 fusion treated with conventional therapy in another report) 37 had a late relapse after completion of therapy. Both relapsed patients who were initially Probability Time (years) treated with low-risk therapy in this study are long-term survivors after retrieval chemotherapy. Thus, in the setting of limited resources, screening for BCR-ABL1-like ALL may not be necessary for low-risk patients with negative MRD after remission induction and may be reserved for those with refractory or high-risk ALL, especially patients with high levels of MRD, and for patients with relapsed B-ALL. If our finding of the lack of t(1;19)(TCF3-PBX1), t(4;11)(MLL-AFF1), or t(12;21)(ETV6-RUNX1) in BCR-ABL1-like ALL is confirmed by additional studies, patients with these genetic abnormalities could also be excluded from screening. However, detailed genomic studies were not performed in both relapsed patients with BCR-ABL1-like ALL in the low-risk group in this study. Conceivably, they had genetic lesions responsive to tyrosine kinase inhibitors. Thus, additional studies are still needed to characterize the low-risk patients. In summary, the advances in cure rates brought about by contemporary MRD-based treatment of childhood ALL have extended to patients with BCR-ABL1-like ALL despite their initial inferior response to treatment. Identification of this ALL subtype and administration of targeted therapy may further improve overall cure rates beyond 90% achieved in some of the contemporary clinical trials 38 and improve their quality of life. BCR-ABL1-like ALL (n = 39) Other B-ALL (n = 302) P = .99
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Fig 3.
Cumulative risk of (A) isolated hematologic relapse or (B) any relapse for patients with BCR-ABL1-like acute lymphoblastic leukemia (ALL) and other B-cell ALL (B-ALL) subtypes. Five-and 10-year rates are reported as means Ϯ SE. Abbreviations: ALL, acute lymphoblastic leukemia; B-ALL, B-cell ALL. ‫ء‬ Based on minimal residual disease levels measured on days 19 and 46 of remission induction.
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Identification of two novel mutant alleles of human TPMT, and Abbreviations: EFS, event-free survival; HR, hazard ratio; MRD, minimal residual disease; OS, overall survival.
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